Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma

NCT06161545 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

NIH

Sponsor class

Conditions

Stage II Squamous Cell Carcinoma of the Head and Neck
Stage III Squamous Cell Carcinoma of the Head and Neck
Stage IV Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL: PD-L1 t-haNK cells
DRUG: pembrolizumab
DRUG: N-803

Sponsor

National Cancer Institute (NCI)